The tyrosine kinase inhibitor AMN107 (Nilotinib) exhibits off-target effects in lymphoblastic cell lines

Leukemia and Lymphoma

Volumn 48, Issue 7, 2007, Pages 1379-1388

  Chow, Kai Uwe ^a,b   Nowak, Daniel ^c   Trepohl, Bettina ^a   Hochmuth, Simone ^a   Schneider, Bernd ^a   Hoelzer, Dieter ^a   Mitrou, Paris S ^a   Bergmann, Lothar ^a   Ottmann, Oliver Gerhard ^a   Boehrer, Simone ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Medizinisches Versorgungszentrum   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

AMN107; Apoptosis; Src kinases; Tyrosine kinase inhibitor

Indexed keywords

AMINOPYRIDINE; BCR ABL PROTEIN; CASPASE 6; CASPASE 9; CASPASE INHIBITOR; HEMATOPOIETIC CELL KINASE; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE LCK; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PHOSPHORYLATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; INCUBATION TIME; LYMPHOBLAST; LYMPHOID CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CELL LINE, TUMOR; HUMANS; LEUKEMIA, LYMPHOCYTIC; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SRC-FAMILY KINASES; T-LYMPHOCYTES;

EID: 34447576823     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701385181     Document Type: Article

References (20)

1. Verstovsek, S., Golemovic, M., Kantarjian, H., Manshouri, T., Estrov, Z. and Manley, P. (2005) AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer, 104, pp. 1230-1236.
2. Chow, K. U., Nowak, D., Hofmann, W., Schneider, B. and Hofmann, W. K. (2005) Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4. Leukemia, 19, pp. 1103-1105.
3. Boehrer, S., Nowak, D., Hochmuth, S., Kim, S. Z., Trepohl, B. and Afkir, A. (2005) Daxx overexpression in T-lymphoblastic Jurkat cells enhances caspase-dependent death receptor and drug-induced apoptosis in distinct ways. Cell Signal, 17, pp. 581-595.
4. Chow, K. U., Nowak, D., Boehrer, S., Ruthardt, M., Knau, A. and Hoelzer, D. (2003) Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol, 66, pp. 711-724.
5. Song, G., Ouyang, G. and Bao, S. (2005) The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med, 9, pp. 59-71.
6. Wendel, H. G., De Stanchina, E., Fridman, J. S., Malina, A., Ray, S. and Kogan, S. (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature, 428, pp. 332-337.
7. Pelengaris, S., Khan, M. and Evan, G. (2002) c-MYC: More than just a matter of life and death. Nat Rev Cancer, 2, pp. 764-776.
8. Dang, C. V. (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol, 19, pp. 1-11.
9. Eilers, M. (1999) Control of cell proliferation by Myc family genes. Mol Cells, 9, pp. 1-6.
10. Lysechko, T. L. and Ostergaard, H. L. (2005) Differential Src family kinase activity requirements for CD3 zeta phosphorylation/ZAP70 recruitment and CD3 epsilon phosphorylation. J Immunol, 174, pp. 7807-7814.
11. Huntington, N. D. and Tarlinton, D. M. (2004) CD45: Direct and indirect government of immune regulation. Immunol Lett, 94, pp. 167-174.
12. Wange, R. L. (2004) TCR signaling: Another Abl-bodied kinase joins the cascade. Curr Biol, 14, pp. R562-R564.
13. Byrd, J. C., Stilgenbauer, S. and Flinn, I. W. (2004) Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program, pp. 163-183.
14. O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W. and Mestan, J. (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res, 65, pp. 4500-4505.
15. Mateyak, M. K., Obaya, A. J. and Sedivy, J. M. (1999) c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol, 19, pp. 4672-4683.
16. Furstoss, O., Manes, G. and Roche, S. (2002) Cyclin E and cyclin A are likely targets of Src for PDGF-induced DNA synthesis in fibroblasts. FEBS Lett, 526, pp. 82-86.
17. Riley, D., Carragher, N. O., Frame, M. C. and Wyke, J. A. (2001) The mechanism of cell cycle regulation by v-Src. Oncogene, 20, pp. 5941-5950.
18. Mamidipudi, V., Zhang, J., Lee, K. C. and Cartwright, C. A. (2004) RACK1 regulates G1/S progression by suppressing Src kinase activity. Mol Cell Biol, 24, pp. 6788-6798.
19. Plattner, R. and Pendergast, A. M. (2003) Activation and signaling of the Abl tyrosine kinase: Bidirectional link with phosphoinositide signaling. Cell Cycle, 2, pp. 273-274.
20. Plattner, R., Koleske, A. J., Kazlauskas, A. and Pendergast, A. M. (2004) Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol Cell Biol, 24, pp. 2573-2583.